Consensus on HER2-ultralow definitions and HER2 testing standardization is essential for the timely identification and treatment of patients with HER2-low or HER2-ultralow breast cancers who may benefit from T-DXd therapy. This evidence concerns the gene ERBB2 and breast cancer.